This phase I/II trial is evaluating the safety and recommended dose of a combined targeted therapy (BGB-A425 and Tislelizumab) in patients with advanced solid cancers.
This trial is treating patients with advanced solid cancers.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has spread to other parts of the body.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have previously been treated (or are currently being treated) on a clinical trial.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Phase 1-2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-TIM-3 Monoclonal Antibody BGB-A425 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
BeiGene Australia Pty Ltd
This trial has three parts; dose escalation (phase I), dose expansion (phase II) and a China sub-study.
Recruiting Hospitals Read More